We previously found that the myeloid cell surface glycoprotein CD13 (gp150) is identical to aminopeptidase N (EC 3.4.1 1.21, a widely distributed membrane-bound, zincdependent metalloprotease with an extracellular enzymatic domain that cleaves N-terminal amino acid residues from oligopeptides (J Clin Invest 83:1299, 1989). As a first step toward defining the function of this molecule on myeloid cells, we assessed cell surface-associated Nterminal peptidase activity by sensitive spectrophotometric measurements of the cleavage of pnitroanilide amino acid derivatives. Aminopeptidase activity detected on the surface of normal and malignant hematopoietic cells coincided with the level of cell surface CD13 expression as measured by flow cytometry. The enzyme was specifically inhibited by the zinc-binding metalloprotease inhibitors, bestatin, 1.1 0-phenanthroline, or 2.2'-dipyridyl, but was not affected by several inhibitors of other classes of proteases. Aminopeptidase activity was demonstrated for CD13 molecules specifically immunoprecipitated from the HE CELL SURFACE glycoprotein CD13 (gp150) was T originally recognized as a marker for subsets of normal and malignant hematopoietic cells of the myeloid lineage.'.'' It is now predicted to be identical to a prominent metalloprotease, aminopeptidase N (EC 3.4.11.2), as judged from the deduced amino acid sequence of a biologically active cDNA clone." CDl3/aminopeptidase N also appears on the surface of many cells and tissues outside the hematopoietic system, including fibroblasts, intestinal epithelium, renal tubular epithelium, and in synaptic membranes of the central nervous system.12-" This membrane-bound enzyme cleaves Nterminal amino acids from oligopeptides, with a preference for neutral residues.16 Its activity therefore differs from that of CDlO/neutral endopeptidase (EC 3.4.24.1 1; NEP), another membrane-bound metalloprotease that recognizes cleavage sites at the aminoterminal side of hydrophobic residues. I7-* O We now show that CD13 molecules expressed by normal surface of CD13-positive cells and was blocked by the metalloprotease inhibitor 1 ,lo-phenanthroline. Moreover, cell surface aminopeptidase activity was partially inhibited when viable cells were incubated with two of a panel of 11 monoclonal antibodies (MoAbs) known to be specific for extracellular epitopes of human CD13. This inhibition was apparent in the absence of detectable downmodulation of CD13 molecules from the cell surface, suggesting that these MoAbs either physically interfere with substrate binding or alter the zinc-coordinating properties of aminopeptidase N molecules. Aminopeptidase N could play an important role in modulating signals generated by peptides at the surface of myeloid cells, either by removing key N-terminal residues from active peptides or by converting inactive peptides to active forms. The inhibitory antibodies used in this study should prove useful in delineating the physiologic roles of CDlB/aminopeptidase N on normal and malignant myeloid cells. 0 1990 by The American Society of Hematology.
and malignant human myeloid cells have N-terminal peptidase activity. The aminopeptidase activity was blocked by metalloprotease inhibitors and by binding of two monoclonal antibodies (MoAbs) specific for extracellular epitopes of CD13.
MATERIALS AND METHODS
Normal human mononuclear cells and granulocytes were isolated by Ficoll-Hypaque density gradient centrifugation of heparin-anticoagulated peripheral blood from normal adult volunteers, as previously described." In some experiments, mononuclear cells were cultured overnight in RPMI 1640 medium supplemented with 1-glutamine, 10% fetal calf serum (FCS), 10 mmol/L HEPES, and antibiotics, allowing monocytes to adhere to plastic. Nonadherent cells enriched for lymphocytes were collected, and adherent cells enriched for monocytes were harvested after mechanical scraping. Murine NIH-3T3 fibroblasts engineered to express high levels of human CD13 by introducing a retroviral vector containing the CD 13 cDNA clone were previously described." These and all other cell lines (listed in Table 1 ) were maintained in culture in complete medium under standard conditions at 3 7 T .
Cells were washed in cold staining medium (Dulbecco's modified Eagle's medium, supplemented with 10% FCS, 1-glutamine, 10 mmol/L HEPES, antibotics, and 2 mmol/L sodium azide), and stained as previously described.'' Briefly, cells were incubated at 4OC for 30 minutes in a titered excess of either a CD13-specific MoAb or an isotype-matched control mouse myeloma protein. After two washes with cold staining medium, the cells were incubated for 30 minutes at 4OC with fluoresceinated affinity-purified goat antiserum to mouse immunoglobulin (FITC-GAM; Coulter Immunology, Hialeah, FL). After two more washes in cold staining medium, cells were resuspended at 5 x los cells/mL in staining medium containing 0.25 mmol/L propidium iodide and then analyzed with a Coulter EPICS 753 flow cytometer (Coulter). The fluorescence intensity of CD13-positive cells was determined relative to the background fluorescence intensity of cells stained with an isotype-matched control mouse myeloma protein, where a value of 1.0 reflects fluorescence equivalent to background.
Cells and cell culture.
Flow cytometric analysis. Enzymaric assay. The presence of aminopeptidase N activity was detected spectrophotometrically by monitoring the increase in optical density at 405 nm (OD405) of a solution containing either alanine-p-nitroanilide (Ala-PNA) or proline-p-nitroanilide (Pro-PNA;Sigma, St Louis, MO).*' Ala-PNA is sensitive to aminopeptidase N cleavage, whereas Pro-PNA is resistant. Cleavage of the amino acid residue from either of these compounds results in an accumulation of free p-nitroaniline with a concomitant increase in OD405 (ems = 9,620 mol/L-' ~m -' ) .~' Specific rates of cleavage of Ala-PNA were computed from changes in OD405 after subtraction of the background rate of substrate degradation in the absence of enzyme or cells. Purified bovine alanine aminopeptidase (4 mU/mL; Sigma) was used as a positive control for cleavage of alanine from Ala-PNA. Assays of cell surface enzymatic activity were performed by incubating 2 to 5 x lo5 cells in 0.5 mL of 50 mmol/L isotonic phosphate-buffered saline, pH 7.0 (PBSSO) in the presence of 6 mmol/L Ala-PNA substrate at 37OC. Substrate concentrations of 6 mmol/L were sufficient to obtain maximal enzyme activity. Aliquots were periodically removed and quickly chilled by the addition of three volumes of ice-cold PBSSO on ice, to arrest enzymatic activity. (Cells at 4OC displayed no detectable enzymatic activity.) After centrifugation for 5 minutes at 4OC, cell-free supernatants were assayed for OD405 relative to PBSSO. All measurements were made in triplicate.
In some experiments, assays were performed in the presence of enzyme inhibitors at the concentrations indicated in Table 2 . Bestatin, 1 ,I 0-phenanthroline, 2,2'-dipyridyl, D,L-thiorphan, phosphoramidon, leupeptin, soybean trypsin inhibitor, aprotinin, and N-carboxymethyl-Phe-Leu were all purchased from Sigma Chemicals (St Louis, MO).
To assay for inhibition of enzymatic activity due to binding of CD13-specific MoAbs, we incubated cells at 37OC for 1 hour in PBSSO containing a titered excess of dialyzed CDl3-specific MoAb, followed by addition of Ala-PNA to the cell suspension at a concentration of 6 mmol/L and subsequent sampling for enzymatic activity. Aliquots were quickly chilled after the one-hour incubation, washed, counterstained with FITC-GAM, and analyzed by flow cytometry for postincubation levels of CD13 expression.
Other procedures. Cells were metabolically labeled with ["S]methionine for 1 hour, incubated an additional hour with medium containing unlabeled methionine, lysed, and immunoprecipitated with either CD13-specific MoAbs (an equal mixture of WM47, Mou28, Mou48, and MY7) or isotype-matched control mouse myeloma protein, as previously described." Protein-ASepharose CL-4B (Phamacia Fine Chemicals, Piscataway, NJ), coated with goat antibody to mouse immunoglobulin, was used as the immunoabsorbent. A portion of each immunoprecipitate was washed twice in cold PBSSO supplemented with 0.05 mmol/L zinc acetate (PBS50/zinc),18 resuspended in 0.5 mL PBSSO/zinc containing 6 mmol/L Ala-PNA, incubated at 37OC, and assayed for enzymatic activity. The remainder of the immunoprecipitates were heat denatured and analyzed on polyacrylamide gels containing sodium dodecyl sulfate (SDS), as previously described."
RESULTS
Aminopeptidase activity on the surface of CD13-positive cells. Intact cells were assayed for surface N-aminopeptidase activity with a sensitive spectrophotometric assay that detects the liberation of free p-nitroaniline from amino acid-p-nitroanilide derivatives (Fig 1) . The rates of cleavage of alanine from Ala-PNA for multiple cell lines are summarized in Table 1 . Enzymatic cleavage of proline from Pro-PNA was not observed in the presence of any of the cell types or purified bovine alanine aminopeptidase, consistent with the known pattern of substrate preference of aminopeptidase N. 16 The level of cell surface expression of CD13, monitored by flow cytometry, generally correlated with the measured enzymatic cleavage of Ala-PNA substrate (Table 1) . Each human myeloid and fibroblast cell line was positive for cell surface CD13 expression by flow cytometry and for enzymatic activity by our assay. Conversely, each lymphoid cell line lacked significant enzymatic activity and cell surface CD 13 expression. Peripheral blood mononuclear cells (PBMCs) enriched for monocytes, as well as purified granulocytes, displayed CD13 expression by flow cytometry and had detectable aminopeptidase activity, whereas lymphocyteenriched mononuclear cells were negative by both techniques. The one exception to the close correlation of CD13 expression with enzymatic activity was found in experiments with the parental murine fibroblast NIH-3T3 cell line, which displayed enzymatic activity similar to the human fibroblast cell lines VA-2 and HEL but did not bind MoAbs specific for human CD13. The panel of CD13-specific MoAbs, all raised by immunization with human CD13-expressing cells, did not react with murine fibroblast (NIH-3T3) or murine macrophage (BAC1.2F5) cell lines (data not shown), even though these cells would be expected to express murine homologs of CD13. These findings suggest, then, that a murine CD13 homolog is expressed by these cells and has aminopeptidase N activity, but that the MoAbs react only with epitopes restricted to human CD13 molecules.
Cell surface aminopeptidase N activity was abrogated by the metalloprotease inhibitors bestatin, 1,lO-phenanthroline and 2,2'-dipyridyl, but not by compounds that inhibit other classes of proteases ( Table 2 ). The latter group included phosphoramidon, D,L-thiorphan, and N-carboxymethyl-Phe-Leu, all known to inhibit CDlO/neutral end~peptidase.*~-'~ Substantial inhibition of aminopeptidase N was also observed after incubation with the two CD13-specific MoAbs, WM15 and F23 ( minimal inhibitory activity. Enzymatic activity was reduced to 15% of uninhibited levels after incubation of CD13-positive cells with a titered excess of either WM15 or F23 (Fig 2) . Incubation with a mixture of maximally inhibiting concentrations of both antibodies did not increase the level of inhibition over that of either MoAb alone, suggesting that these two MoAbs may recognize the same extracellular epitope of CD13 molecules. When NIH-3T3 cells genetically engineered to express human CD13 were investigated, the level of N-terminal peptidase activity after maximal MoAb inhibition with either WMlS or F23 still exceeded that observed for the parental cell line (Table 1; AMINOPEPTIDASE N ACTIVITY OF CD13 500 -activity above that attributable to murine CD13 that was not inhibited by the MoAbs could be due to incomplete inhibition of cell surface CD 13/aminopeptidase N or to intracellular forms of the molecule that are accessible to substrate (which may penetrate the plasma membrane) but not to the antibodies. Alternatively, the residual activity could be due to other cell surface or cytoplasmic aminopeptidases that do not react with CD13-specific MoAbs. The WM15 preparation used in these tests was ascites fluid, whereas the F23 preparation was partially purified protein, which would account for the differences in effective titers that were observed for the two antibodies.
Inhibitory antibodies do not induce CD13 downmodulation. Cells incubated with MoAbs were analyzed in parallel by flow cytometry to determine if MoAb binding might induce CD13 downmodulation, a possible explanation for loss of cell surface enzymatic activity. Cell surface expression of CD13 after 1 hour of incubation with each of the 11 CD13-specific MoAbs was identical to that seen on freshly harvested and stained cells (Figs. 3A, B) , indicating that exposure to MoAb did not induce loss of CD13 molecules from the cell surface. This result contrasts with that reported for CDlO/NEP, which is substantially downmodulated after incubation with CD10-specific MoAbs.*'
To compare the effects of MoAb binding to CDlO with those observed for CD13, we incubated CDlO-positive NALM-1 cells with a titered excess of the CD10-specific MoAb 3-2A3 for 1 hour at 37OC, and compared postincubation CDlO levels with those on freshly isolated NALM-1 cells. Substantial CDlO downmodulation was observed after exposure to MoAbs (Fig 3C) , in contrast to the pattern observed after incubation of CD13-positive cells with CD13-specific MoAbs.
Aminopeptidase activity of CD13 immunoprecipitates. A mixture of four CD13-specific MoAbs (WM47, Mou28, Mou48, and MY7) specifically immunoprecipitated two [35S]methionine-labeled polypeptides of 130,000 and 150,000 mol wt from lysates of metabolically labeled NIH-3T3 transformants that express high levels of CD13 (Fig 4, lane  4) . These glycoproteins are the immature precursor and mature cell surface forms of CD13, respectively, as demonstrated in previous studiesz2 Neither polypeptide was immunoprecipitated from the CDl3-positive transformants by control mouse myeloma protein (lane 3), nor were they immunoprecipitated from parental NIH-3T3 cells with use of either the CD13-specific MoAb mixture or control mouse myeloma protein (lanes 1 and 2) .
Portions of each immunoprecipitate were used for enzymatic assays after incubation in PBSSO/zinc, which replenished the metal cofactor needed by the enzyme." Only the polypeptides immunoprecipitated from NIH-3T3 transformants with the CDI 3-specific MoAb mixture had detectable aminopeptidase N activity; control immunoprecipitates were completely negative for enzymatic activity (Fig 5 ) . Additionally, when tested in the presence of inhibiting levels of 1,lO-phenanthroline (1.5 mmoljl), an aliquot of the enzymatically active CD13 immunoprecipitate was inhibited to background levels. 
-.

DISCUSSION
The myeloid cell surface glycoprotein CD13 has aminopeptidase activity, as predicted by the recently reported sequence identity between CD13 and aminopeptidase N.1'328 First, the activity of the enzyme on the surface of intact cells paralleled the cell surface expression of human CDI 3 molecules, as detected by flow cytometry. Second, the pattern of cleavage of N-terminal alanine and the virtual lack of cleavage of N-terminal proline coincided with the documented substrate preference of aminopeptidase N.I6 Third, cell surface aminopeptidase activity was completely blocked by known inhibitorsof the enzyme (bestatin, 1 .IO-phenanthroline, and 2,2'-dipyripdyl) but was unaffected by other compounds that inhibit proteases of other classes. Fourth, two MoAbs that recognize extracellular epitopes of human CDI 3 abolished most of the enzymatic activity on the surface of murine fibroblasts engineered to express high levels of CDI 3 and on human HL60 cells. Finally, cell surface CD13 molecules specifically immunoprecipitated by anti-CDI 3 MoAbs were shown to have aminopeptidase N activity in vitro that was inhibited by 1,IO-phenanthroline.
Aminopeptidase N is one of many cell surface peptidases that are found in a spectrum of tissues. The wide distribution of this and other ectoenzymes suggests that they perform multiple functions that may be site dependent.".'" However, the potential actions of aminopeptidase N are limited by its substrate specificity. The enzyme cleaves N-terminal amino acids from small peptides that are unblocked at the amino terminus," with the length of the substrate peptide chain affecting the rate of enzyme activity."." Maximal rates of cleavage are obtained for small oligopeptides, whereas large proteins are poor substrates, suggesting that undenatured proteins generally may not have accessible sites for enzymatic cleavage by this ectoenzyme.
An undisputed function of aminopeptidase N, exemplified by its activity on the brush border of intestinal epithelial cells, is to cleave N-terminal amino acids from small peptides in the final stages of protein digestion."." Hence, the enzyme performs a nutritional protein processing role with other ectoenzymes that appear on the extracellular surface. Perhaps of greater interest with respect to cell regulation is the enzyme's postulated negative regulatory role as an inactivator of bioactive oligopeptide~."~'~~'~ Interestingly. aminopeptidase N participates with CDIO/NEP in the enzymatic inactivation of bioactive peptides in the brain and other tissues (reviewed in reference 32). On synaptic membranes of the central nervous system, aminopeptidase N provides a major enkephalin-and endorphin-degrading activity, hydrolyzing the N-terminal Thrl-Gly' bond common to a whole family of opioid peptides. participates by cleaving internal peptide bonds such as the Gly3-Phe4 bond shared by these compounds. Aminopeptidase N also has been implicated in the inactivation of neurokinin A," and may contribute to cholecystokinin m e t a b o l i~m .~~ In the presence of specific inhibitors of either N E P or aminopeptidase N , the effects of susceptible bioactive peptides are prolonged.26s37
Whether CD13/aminopeptidase N on normal or malignant myeloid cells acts as an amino acid scavenger, a regulatory enzyme, or serves some other function has not been determined, although clues are available from investigations of the effects of enzyme inhibitors on mature myeloid cells. In vivo and in vitro administration of bestatin, a potent inhibitor of multiple aminopeptidases, produces a range of enhanced effects presumably kept in check by these enzymes, including increases in phagocytosis, mitogenesis of T cells in mixed macrophage/lymphocyte cultures, and immune responses to antigen and tumor cell stim~li..'~-~* These effects closely parallel those produced by a series of small bioactive peptides, including tuftsin, which exert their effects on circulating monocytes and neutrophils. Exposure of myeloid cells to tuftsin results in stimulation of phagocytosis, motility, bactericidal and tumoricidal activity, mitogenesis, and antibody production by mixed lymphocyte cultures (reviewed in reference 43). Tuftsin, a tetrapeptide (Thr-Lys-ProArg), is liberated from fragments of immunoglobulin molecules in part by the action of an ectoenzyme ("leukokinase") on the surface of phagocytic and it acts through a distinct receptor that is expressed on the surface of these ~e l l s .~~.~~ Aminopeptidase N liberates the N-terminal Thr residue of tuftsin, transforming the tetrapeptide into an inactive tripeptide (Lys-Pro-Arg) that competitively inhibits tuftsin-binding to its receptors.46 Thus, phagocytic cells express cell surface enzymes necessary for generating stimulatory peptides from naturally occurring substrates, as well as aminopeptidase N molecules that can inactivate and terminate responses to these compounds.
It may be important that myeloid progenitors and mature monocytes and macrophages express C D 1 3/aminopeptidase N but not CDIO/NEP, whereas lymphoid progenitors express CDlO/NEP but not CD13/aminopeptidase N.'-10947-50
Differential expression of these two metalloproteases may indicate unique interactions of progenitors within these lineages with regulatory peptides that affect cell proliferation or differentiation. Inhibitory anti-CD13 MoAbs should prove useful in further studies of the precise role of aminopeptidase N on the surface of normal and malignant myeloid cells.
